Alexza Pharmaceuticals Inc, Palo Alto, Calif—makers of a promising new
insomnia drug—have named Robert S. Fishman, MD, FCCP, as vice president,
medical affairs.
Fishman’s primary responsibilities will be in the development and execution
of strategies for Alexza’s multiple clinical product candidates and for
medical oversight of all of the company’s clinical programs.
Alexza’s patented Staccato system creates aerosolized delivery modes of
their top drugs for ease of inhalation and speed of therapeutic onset. There
are six Stacatto system candidates in the pipeline including AZ-007
(Staccato zaleplon) for the treatment of sleep disorders in patients who
have difficulty falling asleep.
To read full release, [removed]click here[/removed].